Maojin You
Ningde, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5.
Journal: Frontiers in public health
Published: April 04, 2025
Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
Journal: Frontiers in immunology
Published: February 12, 2025
Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer.
Journal: Frontiers in immunology
Published: August 07, 2024
Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial.
Journal: Frontiers in pharmacology
Published: April 04, 2024
Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.
Journal: Frontiers in immunology
Published: July 26, 2023
Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
Journal: Frontiers in pharmacology
Published: June 10, 2023
Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.
Journal: Frontiers in pharmacology
Published: May 09, 2023
SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
Journal: Annals of clinical and laboratory science
Published: December 23, 2022
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.
Journal: Frontiers in pharmacology
Published: August 15, 2022
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers.
Journal: Frontiers in pharmacology
Published: February 08, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026